Advances in media optimization, cell engineering, and AI are reshaping intensified bioprocessing for higher productivity, better quality, and greater manufacturing efficiency.
A $380 million deal between Bristol Myers Squibb and the start-up Cellares is a sign of growing demand for cell and gene therapy manufacturing services. Cellares raised $255 million in a series C ...
It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results